Última Hora: "Google discorda ?respeitosamente? da multa da Comissão Europeia e admite apresentar recurso - Expresso" Tue, 27 Jun 2017 12:00:50 GMT    "Do Porto à estação do Tua, num comboio dos anos 40 - Público.pt" Tue, 27 Jun 2017 06:44:07 GMT    "Viatura de catering danifica porta de um avião da SATA - Observador" Tue, 27 Jun 2017 10:59:00 GMT    "Uber anuncia alargamento da atividade a toda a costa algarvia - Jornal de Notícias" Tue, 27 Jun 2017 23:59:00 GMT    "Fisco fez apenas um terço das ações de controlo planeadas entre 2009 e 2013 - Jornal de Notícias" Tue, 27 Jun 2017 22:56:41 GMT   "Ataque informático mundial atinge farmacêutica Merck e central nuclear Chernobyl - Expresso" Tue, 27 Jun 2017 18:38:00 GMT    "Rede de tráfico na Segurança Social cobrava até 10 mil euros e ficava com salários de imigrantes - Público.pt" Tue, 27 Jun 2017 12:46:00 GMT    "Elisa Ferreira revela que há "diversos investidores" interessados no Montepio - Diário de Notícias - Lisboa" Tue, 27 Jun 2017 16:19:00 GMT    "Mulher supersticiosa atirou moedas ao motor do avião para dar sorte - Notícias ao Minuto" Tue, 27 Jun 2017 18:29:27 GMT    "Reforma aos 60 anos sem cortes custaria 730 milhões em 2019 - Diário de Notícias - Lisboa" Tue, 27 Jun 2017 23:02:00 GMT      Para mais notícias, clique aqui.

Área de Acesso
       
       
Lembrar Sempre 
(Login BolsaPT & Canal Forex)

Mostrar Notícias:
 Ver notícias de outros activos

Pesquisa de notícias relativas à acção Sepracor Inc. (ordenadas pela data):


Board Change
London South East (registration) (blog)
He has also held senior management positions at Sepracor, Inc. (now Sunovion Pharmaceuticals, Inc.), Accenture plc and GlaxoWellcome plc (now GlaxoSmithKline plc). ?Trevor trained as a microbiologist at University of Reading, obtaining a PhD in ...


Flex Pharma (FLKS) Says Christoph Westphal to Transition From Role as CEO, Remain as Chair; William McVicar ...
StreetInsider.com
Flex Pharma, Inc. (NASDAQ: FLKS), a clinical-stage biotechnology company that is developing innovative and proprietary treatments for cramps and spasticity associated with severe neurological diseases including amyotrophic lateral sclerosis (ALS ...

e mais »

Desloratadine Market Analysis and In-Depth Analysis on Market Dynamics, Emerging Trends, Growth Factors and ...
MilTech
Desloratadine Market Key Players Analysis: Pfizer, Teva, Wante Pharmaceutical?, Novartis India Limited, Mylan, Sepracor, Sandoz, Apollo Pharmaceuticals, GSK, Mayne Pharma Inc, Abhilasha Pharma Pvt, Abbott, Takeda, Schering-Plough, Nanjing Hicin ...

e mais »

InvestorGuide

Cynapsus Therapeutics (CYNA) Stock Doubles on Sunovion Buyout
InvestorGuide
Shares of Cynapsus Therapeutics Inc. (CYNA) were trading up +21.44 or +116.78 percent to $39.80 per share in Thursday's premarket after news broke late yesterday that it would be acquired by Sunovion Pharmaceuticals Inc. Cynapsus Therapeutics stock ...

e mais »

Flex Pharma Names William K. McVicar, Ph.D. as President, Research & Development
Business Wire (press release)
?With their successful partnership from their time at Sepracor, Bill and our CMO, Dr. Tom Wessel, are a great team to rapidly advance our Phase 2 clinical trials in MS, ALS and Charcot-Marie-Tooth with FLX-787 which will be amongst the most advanced ...

e mais »

Frequency Therapeutics Announces its Board of Directors and the Appointment of Marc A. Cohen as Chairman
Business Wire (press release)
The Board Members include Tim Barberich, founder and former CEO and Chairman of Sepracor, Inc. (now known as Sunovion), Marc Kozin, Senior Advisor and former President of L.E.K. Consulting, Robert S. Langer, Sc.D., Frequency Co-founder and the ...

e mais »

Sunovion Pharmaceuticals Inc. Announces Company Name Change
Business Wire (press release)
BUSINESS WIRE)--Sunovion Pharmaceuticals Inc. (Sunovion), formerly Sepracor Inc. (Sepracor), announced today that it has formally changed its name. The change occurs on approximately the one year anniversary of the acquisition of Sepracor by ...

e mais »

TheChronicleHerald.ca (registration)

PEI's BioVectra buys former Sepracor plant in Windsor
TheChronicleHerald.ca (registration)
A Charlottetown drug manufacturer has acquired a mothballed Windsor pharmaceutical plant and plans to reopen the facility in early 2016. BioVectra Inc. purchased the former Sepracor Canada (Nova Scotia) Ltd. facility in May. The Sepracor operation ...
Charlottetown's BioVectra expanding, setting up in WindsorHants Journal

todos os 5 artigos de notícias »

Sunovion Celebrates Five-Year Anniversary Milestone
Business Wire (press release)
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc. (Sunovion) announced today that it is celebrating its five-year anniversary. Sunovion was established in October 2010 following the integration of Sepracor Inc. and Dainippon ...

e mais »

Rewire

Religious Imposition Proponents Find an Ally in the White House
Rewire
Stirrup worked as a senior legislative adviser at Venable LLP from 2003 to 2008. The firm's clients between those years included AstraZeneca Pharmaceuticals, Sepracor Inc, and the National Association of Spine Specialists. Another hire, Anna Pilato, is ...


Genzyme Corporation Pays $5.885 Million To Resolve False Claims Act Allegations; Judgment Involving Cases ...
PR Newswire (press release)
Those defendants include Allergan, Inc., Amgen, Inc., Bradley Pharmaceuticals, Inc., Eisai, Inc., Mallincrodt, Inc., Novo Nordisk, Inc., Reliant Pharmaceuticals, Inc., Sepracor, Inc., and Upsher-Smith Laboratories, Inc. The settlement with Genzyme ...

e mais »

POZEN Announces Retirement of Founder, Chairman and CEO Dr. John R. Plachetka; Adrian Adams Named as CEO
Business Wire (press release)
Prior to joining Sepracor, Mr. Adams was President and Chief Executive Officer of Kos Pharmaceuticals, Inc. until its acquisition by Abbott Laboratories. Mr. Adams has also held general management and senior international and national marketing ...

e mais »

Boston Globe

Sunovion gets OK for its epilepsy drug
Boston Globe
Marlborough biotech Sunovion Pharmaceuticals Inc. is preparing to start selling a new antiseizure pill early next year, following Food and Drug Administration approval of the medication. FDA regulators signed off on Sunovion's first epilepsy drug ...

e mais »

Reuters

Dainippon to buy US drug firm Sepracor for $2.6 billion
Reuters
BOSTON/TOKYO Dainippon Sumitomo Pharma Co Ltd agreed on Thursday to buy U.S. drugmaker Sepracor Inc for $2.6 billion, giving the Japanese firm a big, local sales force in the world's largest drugs market. The deal is the latest in a string of overseas ...


Sunovion Pharmaceuticals Canada Inc. Announces Company Name Change
Canada NewsWire (press release)
Sepracor Pharmaceuticals, Inc. changes name, maintains commitment to developing scientifically-advanced central nervous system, cardiovascular disease and infectious disease therapies that improve patients' lives. MISSISSAUGA, ON, Aug. 17, 2011 ...

e mais »

PMLiVE

Astellas appoints ethics and compliance and US legal leaders
PMLiVE
Wanda brings over 20 years of experience in the pharmaceutical industry, having held senior leadership positions at Schering-Plough and Sepracor Inc, a US-based biopharmaceutical company. Prior to joining Astellas as deputy general counsel and head of ...


CoLucid Pharmaceuticals Announces Election of Mark Corrigan, MD, to Board of Directors
GlobeNewswire (press release)
Dr. Corrigan was Executive Vice President, Research & Development of Sunovion Pharmaceuticals Inc. (formerly Sepracor Inc.) from April 2003 until December 2009. Prior to joining Sunovion Pharmaceuticals, he spent 10 years with Pharmacia & Upjohn, Inc.

e mais »

Crain's Detroit Business

Detroit-based Trimaran Pharma attracts experienced executives
Crain's Detroit Business
based Sepracor Inc. when it launched Lunesta, an insomnia drug that was later named by Forbes Magazine as the fifth most successful launch in pharma history, eventually surpassing $1 billion in annual sales. Piskorski also has startup experience.


CEO Adrian Adams Is Prepping Aralez For A Sale
Seeking Alpha
Aralez has an approval for Yosprala, a revenue-generating set of products, and two acquisitions that can make it money. Its bull thesis considers those as positives while the bear focuses on the debt that goes with the package. CEO Adrian Adams, with a ...


Cabot Corporation Names New Vice President of Investor Relations
Business Wire (press release)
Prior to joining Cabot, Mr. Delahunt held several senior financial positions including Vice President and Treasurer for Sepracor Inc. and Vice President and Treasurer for PerkinElmer, Inc. Delahunt earned his MBA and BS in Business Administration from ...

e mais »

Allergy Treatment Market (2016 ? 2024) : Key Projections About The Future State Of The Global Industry
MilTech
Later that year, Pfizer Inc. merged with Allergan plc to expand its share in the global drug industry. On the other hand, side effects of immunotherapy and high cost of this treatment option act as major restraints of the global allergy treatment market.

e mais »

Envisia Therapeutics Appoints William Yelle Executive Chairman
PR Newswire (press release)
Prior to Aldea, Yelle was Senior Vice President of Corporate Development for Sunovion Pharmaceuticals Inc. (formerly Sepracor Inc.). While at Sepracor, he was instrumental in the company's transition from an early stage clinical organization into a ...

e mais »

Drugmaker Sepracor Accepts $2.6B Buyout Offer from Japan's Dainippon
Xconomy
In what could become Massachusetts' largest life science deal of the year, Marlborough, MA-based drugmaker Sepracor (NASDAQ:SEPR) has agreed to be acquired by the Japanese pharmaceutical firm Dainippon Sumitomo Pharma for a whopping $2.6 ...
Another Japanese Drugmaker Makes Another Foreign AcquisitionWall Street Journal Blogs (blog)

todos os 485 artigos de notícias »

Kala Pharmaceuticals Appoints Mark Iwicki as Executive Chairman
Business Wire (press release)
BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (Kala), a developer of innovative ophthalmic products based on its proprietary mucus-penetrating particle (MPP) technology, today announced the appointment of Mark Iwicki as Executive Chairman and a ... Mr ...

e mais »

Boston Globe

FDA approves Marlborough company's epilepsy drug
Boston Globe
An epilepsy tablet made by Marlborough-based Sunovion Pharmaceuticals Inc. won US approval Friday to be sold as a primary therapy for hundreds of thousands of Americans suffering from partial-onset seizures. The drug, called Aptiom, has been on the ...

e mais »

Cincinnati.com

Healthwarehouse.com gets a new leader
Cincinnati.com
Florence-based online pharmacy HealthWarehouse.com Inc. has a new leader. John Pauly was appointed chief operating ... 12 years at pharmaceuticals company Sepracor. Before joining Sepracor, Pauly worked at Richwood Pharmaceuticals and Centocor.


Medscape

Dietary Supplement Kit May Head Off Postpartum Blues
Medscape
A dietary supplement kit containing tryptophan, tyrosine, and blueberry juice/extract appears to markedly reduce vulnerability to postpartum blues (PPB), a new open-label study suggests. "The supplement taken on days 3 to 5 post partum had a very ...


Overview of Consultation-Liaison Psychiatry: April 2017
Healio
Andrew A. Nierenberg, MD, has disclosed the following relevant financial relationships: Appliance Computing Inc. (Mindsite); Astra Zeneca; Brain Cells, Inc.; Brandeis University; Bristol Myers Squibb; Clintara, Dianippon Sumitomo/Sepracor; Eli Lilly ...


Mylan, Sunovion Reach Terms In Xopenex Patent Fight
Law360 (subscription)
Law360, New York (May 29, 2012, 5:50 PM EDT) -- Mylan Inc. said Tuesday it had settled a patent fight with Sunovion Pharmaceuticals Inc. over the asthma drug Xopenex, in a deal that will allow Mylan to continue selling its own version of the drug and ...

e mais »

San Francisco Business Times (blog)

Can depression be treated like cancer? This startup thinks so
San Francisco Business Times (blog)
Uncovering ways that cancer exploits cellular weakness, researchers have discovered new treatments that attack those specific pathways. Now a Bay Area biotech startup wants to take that mindset to depression and other mental disorders. BlackThorn ...
BlackThorn Therapeutics Launches to Develop Novel, Targeted Treatments for Neurobehavioral DisordersBusiness Wire (press release)

todos os 7 artigos de notícias »

Largura do Site:

 Imagem de Fundo:

Copyright@1998-2017 - BolsaPT.com, todos os direitos reservados.
Fórum de Bolsa Cotações de Bolsa Notícias de Bolsa Chat de Bolsa Disclaimer Recursos para Webmasters